- Book
- April 2022
- 480 Pages
- Book
- April 2022
- 576 Pages
- Book
- December 2021
- 624 Pages
- Book
- September 2021
- 464 Pages
- Book
- April 2021
- 6032 Pages
€4117EUR$4,465USD£3,333GBP
- Book
- July 2020
- 416 Pages
- Book
- February 2020
- 128 Pages
- Book
- June 2018
- 368 Pages
- Book
- November 2024
- 576 Pages
- Book
- August 2024
- 432 Pages
- Book
- February 2024
- 928 Pages
- Book
- January 2016
- 360 Pages
- Book
- April 2012
- 268 Pages
- Book
- March 2012
- 450 Pages
- Book
- August 2010
- 355 Pages
- Book
- January 2009
- 408 Pages
- Book
- December 2011
- 492 Pages

The Drug Metabolism market within the context of Biotechnology is a rapidly growing sector, with a focus on the development of new drugs and treatments. It involves the study of how drugs are broken down and metabolized in the body, and how this affects their efficacy and safety. This market is driven by the need for more effective and safer drugs, as well as the increasing demand for personalized medicine. Companies in this market are developing new technologies to improve drug metabolism, such as artificial intelligence and machine learning. They are also exploring new ways to identify and target drug metabolism pathways, as well as developing new drug delivery systems.
Some companies in the Drug Metabolism market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more